These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 2109558

  • 21. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.
    Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL.
    Am Rev Respir Dis; 1985 Oct; 132(4):761-5. PubMed ID: 3931522
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
    Ordoñez CL, Henig NR, Mayer-Hamblett N, Accurso FJ, Burns JL, Chmiel JF, Daines CL, Gibson RL, McNamara S, Retsch-Bogart GZ, Zeitlin PL, Aitken ML.
    Am J Respir Crit Care Med; 2003 Dec 15; 168(12):1471-5. PubMed ID: 12969869
    [Abstract] [Full Text] [Related]

  • 32. Experimental Pseudomonas aeruginosa sepsis: absence of synergy between ticarcillin and tobramycin.
    Chusid MJ, Davis SD, Sarff LD.
    J Lab Clin Med; 1983 Mar 15; 101(3):441-9. PubMed ID: 6402553
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Assael BM.
    Expert Rev Anti Infect Ther; 2011 Nov 15; 9(11):967-73. PubMed ID: 22029514
    [Abstract] [Full Text] [Related]

  • 35. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R.
    Ann Pharmacother; 2005 Jan 15; 39(1):39-44. PubMed ID: 15562142
    [Abstract] [Full Text] [Related]

  • 36. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D.
    Clin Ther; 2013 Oct 15; 35(10):1571-81. PubMed ID: 24054830
    [Abstract] [Full Text] [Related]

  • 37. Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients.
    Deneuville E, Perrot-Minot C, Pennaforte F, Roussey M, Zahm JM, Clavel C, Puchelle E, de Bentzmann S.
    Am J Respir Crit Care Med; 1997 Jul 15; 156(1):166-72. PubMed ID: 9230742
    [Abstract] [Full Text] [Related]

  • 38. Application of positive expiratory pressure *PEP* in cystic fibrosis patient inhalations.
    Orlik T, Sands D.
    Dev Period Med; 2015 Jul 15; 19(1):50-9. PubMed ID: 26003070
    [Abstract] [Full Text] [Related]

  • 39. Recombinant human DNase I in cystic fibrosis patients with severe pulmonary disease: a short-term, double-blind study followed by six months open-label treatment.
    Shah PI, Bush A, Canny GJ, Colin AA, Fuchs HJ, Geddes DM, Johnson CA, Light MC, Scott SF, Tullis DE.
    Eur Respir J; 1995 Jun 15; 8(6):954-8. PubMed ID: 7589382
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.